REZDIFFRA continues strong momentum, with Q1 2025 sales up 33% and positive EU regulatory progress, supporting my gradually bullish outlook. Madrigal's financials show an improving net loss and a ...
Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...
Rezdiffra has interactions with certain drugs, such as clopidogrel, atorvastatin, and gemfibrozil. Talk with your doctor to avoid potentially harmful effects from Rezdiffra interactions. Rezdiffra is ...
MDGL’s Rezdiffra is its main value driver. This is the first FDA-approved MASH F2–F3 therapy. So far, Rezdiffra shows a rapid U.S. uptake and market penetration. Management projects over 23,000 ...
Madrigal Pharmaceuticals announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for the patent covering Rezdiffra™ (resmetirom), the only FDA-approved treatment for ...
Company advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple stages of development, anchored by Rezdiffra ® (resmetirom) as the foundational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results